

Intravenous bisphosphonates in the prevention of osteoporosis associated with stroke

Submission date 02/08/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 23/08/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 08/06/2011	Condition category Circulatory System	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Elizabeth Warburton

Contact details
Department of Clinical Neurosciences
Addenbrooke's Hospital
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Protocol serial number
LREC 01/245

Study information

Scientific Title

Study objectives

The aim of this study is to investigate whether reductions in bone mineral density (BMD) in the hemiplegic hip of stroke patients can be prevented with the early use of a single dose of intravenous zoledronate. The study consists of a randomised double-blinded placebo-controlled trial of intravenous zoledronate (4 mg) to prevent bone loss in hemiplegic patients with acute stroke. Bone mineral density in both hemiplegic and unaffected hips of hemiplegic patients will be assessed, and patients will be randomised to receive a single infusion of either 4 mg zoledronic acid or placebo within 35 days of acute stroke. Serial measurements of hip bone mineral density will be made at 6 and 12 months in addition to detailed assessments of stroke recovery, functional status and balance.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Stroke and osteoporosis

Interventions

Intravenous zoledronate 4 mg versus placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zoledronate

Primary outcome(s)

Bone mineral density at the hemiplegic hip 12 months following stroke.

Key secondary outcome(s)

1. Bone mineral density at the unaffected hip 12 months following stroke
2. Histomorphometric analysis of bone biopsies from stroke patients treated with zoledronate or placebo

Completion date

22/09/2005

Eligibility

Key inclusion criteria

For inclusion, males and females aged 40-89 will be approached as soon as possible after admission with first ever stroke. Patients will be eligible if they were previously independently walking, have clinical and computed tomography (CT) evidence of stroke (haemorrhagic or ischaemic), are unable to walk 1 week following stroke (Functional Ambulatory Category [FAC] 0 or 1) and can give written informed consent to the study.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Exclusion criteria are as follows:

- A. Not walking independently prior to stroke/previous stroke causing hemiplegia
- B. Stroke not affecting the lower limb/FAC >1 at 1 week post stroke/posterior circulation stroke
- C. Unconsciousness or terminal illness
- D. Pre-existing dementia or cognitive impairment
- E. Aphasia/significant language impairment
- F. Renal/hepatic impairment
- G. Aged <40 and >89
- H. Prior treatment with a bisphosphonate, corticosteroids/known osteoporosis/unilateral bone disease affecting BMD/prior hip fracture or osteosynthetic material at the hip (e.g. hip replacement)
- I. Unable to randomise and give infusion within 35 days of stroke (e.g. tertiary referrals from another hospital)
- J. Current treatment with an aminoglycoside antibiotic

Date of first enrolment

01/10/2001

Date of final enrolment

22/09/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Department of Clinical Neurosciences
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation
Cambridge University Hospitals NHS Foundation Trust (UK)

ROR
<https://ror.org/04v54gj93>

Funder(s)

Funder type
Charity

Funder Name
National Osteoporosis Society (UK) RG33985

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2007		Yes	No